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A B S T R A C T
Purpose
We have previously shown that the PAM50-based risk of recurrence (ROR) score is significantly correlated
with distant recurrence in both the translational research cohort within the Arimidex, Tamoxifen Alone or in
Combination (ATAC) trial (TransATAC) andAustrian Breast andColorectal Cancer StudyGroup 8 (ABCSG8)
randomized trials. Here, we focus on the ROR score for predicting distant recurrence after 5 years of
follow-up in a combined analysis of these two randomized trials.
Methods
Long-term follow-up data and tissue samples were obtained from 2,137 postmenopausal women
with hormone receptor–positive early-stage breast cancer from the ABCSG 8 and TransATAC
trials. We used Cox proportional hazard regression models to determine the prognostic value of
ROR for distant recurrence beyond 5 years in the combined data set.
Results
A total of 2,137 women who did not have a recurrence 5 years after diagnosis were included in the
combined analyses. The Clinical Treatment Score (CTS) was the strongest prognostic factor 5
years after diagnosis (univariable: likelihood ratio [LR] 2  94.12, bivariable: LR 2  61.43). The
ROR score was significantly prognostic by itself in years 5 to 10. In the node-negative/human
epidermal growth factor receptor 2–negative subgroup, more prognostic value for late distant
recurrence was added by the ROR score compared with the CTS.
Conclusion
The ROR score added clinically meaningful prognostic information to the CTS in all patients and all
subgroups in the late follow-up period. These results suggest that the ROR score may be helpful
for separating patients into risk groups who could be spared or potentially benefit from extended
hormonal therapy beyond 5 years of treatment.
J Clin Oncol 33:916-922. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Women with estrogen receptor (ER) –positive tu-
mors remain at risk for late recurrences, with the
annual rate in excess of 2% for at least 15 years, even
after 5 years of tamoxifen therapy.1 Currently, it is
not possible to identify a group of women who can
be considered as cured after the initial 5 years of
endocrine therapy.2,3 Most of the studies of
prevention of late relapse have been performed
with women who received tamoxifen as initial
endocrine therapy,4,5 and there are only a few
reports with women who initially received an aro-
matase inhibitor.
It has been reported that women with highly pro-
liferative tumors (a high mitotic kinase score) and a
high estrogen-related score were at greater risk of late
recurrence.6 The Breast Cancer Index (BCI) showed
prognostic ability to assess early and late distant recur-
rence.7 Sgroietal8 reportedonthecomparativeperfor-
mance of the BCI versus immunohistochemical 4
markers and Oncotype Dx recurrence score (RS) for
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late recurrence and found that the BCI is a strong prognostic factor in
predicting laterecurrence.Dubskyetal9 reportedontheEndoPredict test,
which stratifies patients into low- and high-risk groups for late recurrence
(Appendix Table A1, online only).
The risk of recurrence (ROR) score has previously been shown to
add prognostic information not found in standard markers.10,11 In the
translational research cohort within the Arimidex, Tamoxifen Alone
or in Combination (ATAC) trial (TransATAC),12 the performance of
the ROR score was compared with that of the RS and immunohisto-
chemical 4 for distant recurrence in 1,007 postmenopausal women,
and results showed that the ROR added more prognostic informa-
tion in endocrine-treated women with node-negative disease than
the RS. Similarly, the Austrian Breast and Colorectal Cancer Study
Group 8 (ABCSG 8) trial13 showed that the ROR score predicted
the risk of distant recurrence in 1,478 postmenopausal women
with ER-positive early-stage breast cancer. It is important to deter-
mine to what extent the ROR score can help predict late recurrence,
specifically beyond 5 years after diagnosis. Here, we combine the
data from the TransATAC and ABCSG 8 trials and investigate the
extent to which the ROR score predicts for distant recurrence
exclusively in years 5 to 10 after diagnosis.
METHODS
The ATAC trial evaluated the efficacy and safety of anastrozole versus tamox-
ifen given for 5 years in postmenopausal women with localized breast cancer.14
The TransATAC substudy collected formalin-fixed, paraffin embedded blocks
from hormone receptor–positive breast cancers in a subset of women ran-
domly assigned to the monotherapy arms of the ATAC trial.15 The ABCSG 8
trial was a randomized, open-label trial comparing 5 years of tamoxifen with 2
years of tamoxifen followed by 3 years of anastrozole in postmenopausal
women with hormone receptor–positive breast cancer, for whom formalin-
fixed, paraffin embedded blocks from the original tumors were collected to
extract RNA and for use in a subsequent PAM50 analysis.16 Both trials were
performed in accordance with the Declaration of Helsinki (1996 revision),
under the principles of good clinical practice. The ATAC trial is registered as an
International Standard Randomized Controlled Trial (ISRCTN18233230)
and the ABCSG 8 trial is registered under the Clinical Trial Registry
(NCT00291759).
The Clinical Treatment Score (CTS) contains information on nodal
status, tumor size, grade, age, and treatment and was developed on the
TransATAC data set.17 The laboratory methods for the original ROR score
have been described in detail previously.10,17,18 Briefly, the expression levels for
50 classifier genes and eight housekeeping genes were measured by using the
nCounter platform (NanoString Technologies, Seattle, WA), which gives a
ROR score between zero and 100 that is indicative of the probability of distant
recurrence. After normalization, the expression profile of the 50 classifier genes
for each sample was used to determine the intrinsic subtype of the tumor. A
46-gene subset of the PAM50 genes plus tumor size was used to calculate a
predefined ROR score, which performed as well as the ROR score that was
based on the 50-gene set.18 Risk stratification by using the ROR score was
based on the predicted distant recurrence risk at 10 years ( 10%: low-risk
group, ROR 0 to 26; 10% to 20%: intermediate-risk group, ROR 26 to 68;
 20%: high-risk group, ROR 68).
The primary objective of this study was to determine whether the ROR
score provides prognostic information in the period beginning 5 years after
diagnosis. The time from 5 years after diagnosis to the first distant recurrence
after 5 years was the prospectively defined primary end point. Death before
distant recurrence was treated as a censoring event. The association between
ROR score and distant recurrence after 5 years of follow-up was assessed by
using hazard ratios (HRs) derived from Cox proportional hazards regression
models with associated 95% CIs. For bivariable analyses, the ROR score
was added separately to the CTS to determine the added prognostic informa-
tion in that score. Changes in likelihood ratio 2 (LR 2) values were used to
measure and compare the relative amount of information of one score com-
pared with the other. Survival curves were estimated by using the Kaplan-
Meier method. All curves were truncated at 10 years of follow-up because
differential follow-up was available for the two trials thereafter. However,
overall HRs are presented for all events in both trials. The Net Reclassification
Index (NRI) was used to determine the prognostic improvement by ROR
beyond that of the CTS.19,20 P values were two-sided based on normal approx-
imation, and all CIs were at the 95% level. Analyses were performed by using
STATA version 12.1 (STATA, College Station, TX).
RESULTS
The two trials were combined in this analysis and baseline character-
istics are shown in Table 1, and further prognostic baseline factors
according to ROR risk group are shown in Appendix Table A2 (online
only). For this analysis, women who had a recurrence in the first 5
years were excluded; thus, data from both trials included only post-
menopausal women with hormone receptor–positive breast cancer
who received 5 years of endocrine treatment and who did not have a
recurrence in the first 5 years (N 2,137 [1,275 from ABCSG 8; 862
from TransATAC]). The mean ROR score for those women who were
excluded from this analysis (who had a recurrence during the first 5
years) was significantly higher compared with the scores for those who
did not have a recurrence in the first 5 years (53.57 [standard devia-
tion, 20.4] v 41.89 [standard deviation, 19.5]; P .001). The median
follow-up for this analysis was 10 years.21,22 There were 148 distant
recurrences beyond 5 years of follow-up. This analysis focuses only
on the prognostic information obtained for 5 years after diagnosis.
Data are presented for all patients, node-negative patients, node-
positive patients, and human epidermal growth factor receptor 2
(HER2) –negative patients.
There was a significantly higher rate of distant recurrence in years
5 to 10 in the TransATAC trial when compared with the ABCSG 8 trial
(P .001). The TransATAC trial had significantly more women with
large tumors (P  .001), poorly differentiated tumors (none in the
ABCSG 8 trial), and four or more positive nodes. Additional baseline
characteristics for both populations have been described in detail
previously.16,17 An analysis has been performed excluding grade 3
tumors from the TransATAC data set. The omission of these tumors
did not substantially change the results (data not shown). A total of
1,530 women (73.8%) had a luminal A breast cancer subtype and 542
women (26.2%) had a luminal B breast cancer subtype; those with a
luminal B subtype had a 2.9 times higher risk of distant recurrence
(HR, 2.89; 95% CI, 2.07 to 4.02; P .001).
In the overall population, CTS added more prognostic informa-
tion for distant recurrence 5 years after diagnosis in the univariable
analysis (LR 2 94.12) and when added to the ROR score (LR 2
61.43; Table 2). The ROR score also added significant prognostic
information for this time period but somewhat less than the CTS
(univariable LR 2  67.94; bivariable LR 2  35.25). Figure 1
shows Kaplan-Meier curves for the separation of ROR scores into
low-, intermediate-, and high-risk groups based on the 10-year distant
recurrence risk of less than 10%, 10% to 20%, and more than 20%.
Women categorized into the high-risk group had 16.6% (95% CI,
13.1% to 20.9%) risk of distant recurrence in years 5 to 10, those in the
intermediate-risk group had a risk of 8.3% (95% CI, 6.1% to 11.2%),
and those in the low-risk group had a risk of 2.4% (95% CI, 1.6% to
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3.5%; Fig 1). Women in the ROR high-risk group had a 6.9 times
higher risk of late distant recurrence (HR, 6.90; 95% CI, 4.54 to
10.47), and those in the intermediate-risk group had a 3.3 times
higher risk of late distant recurrence (HR, 3.26; 95% CI, 2.07 to
5.13) compared with those in the low-risk group. Figure 2 shows
annual hazard rate curves with corresponding 95% CIs for the
three risk groups. Those in the low-risk group showed stable an-
nual hazard rates under 1% per year between 5 and 10 years,
whereas those in the intermediate-risk group showed an increase
from 1% up to 2% at year 8 (Fig 2). Women in the high-risk group
had an increasing annual hazard rate peaking at 4% at 6.9 years of
follow-up and then stabilized at around 3% per year thereafter.
Results for the main subgroups according to nodal and HER2
status are shown in Table 2 and Appendix Table A3 (online only). In
node-negative patients (n 1,580), the ROR score added more prog-
nostic information than the CTS in both the univariable and the
bivariable analyses (univariable LR 2  30.95 v LR 2  21.48;
bivariable LR 2 17.25 v LR 2 7.79). A similar picture was seen
for the node-negative/HER2-negative subgroup for which more prog-
nostic value for late distant recurrence was added by the ROR score.
Women in the ROR low-risk group had a 2% (95% CI, 1.3% to 3.2%)
risk of distant recurrence by 10 years compared with similar 10-year
distant recurrence rates for those in the intermediate-risk group
(9.0%; 95% CI, 6.3% to 13.0%) and high-risk group (11.5%; 95% CI,
6.8% to 19.0%; Fig 3 and Appendix Table A3). In all, 557 women had
Table 1. Baseline Characteristics According to Trial
Characteristic
TransATAC (n  862) ABCSG 8 (n  1,275)
PNo. % No. %
Treatment (tamoxifen v anastrozole) 412 v 450 629 v 646 .5
Nodal status (negative v positive) 647 v 215 75.1 v 24.9 933 v 342 73.2 v 26.8 .3
Node positive (one to three nodes) 180 20.9 307 24.1
Node positive (four or more nodes) 35 4.1 35 2.8
Tumor size, mm  .001
Mean 19.0 16.7
Standard deviation 10.1 8.3
 10 128 14.8 239 18.7
10-20 459 53.3 699 54.8
20-30 210 24.4 283 22.2
 30 65 7.5 54 4.2
Age ( 65 v  65 years) 504 v 358 58.5 v 41.5 774 v 501 60.7 v 39.3 .3
Differentiation
Well 195 22.6 242 19.0 .04
Moderate 519 60.2 1033 81.0  .001
Poor 148 17.2 — —
Distant recurrence (years 5 to 10) 80 9.3 68 5.3  .001
Abbreviations: ABCSG 8, Austrian Breast and Colorectal Cancer Study Group 8; TransATAC, translational research cohort within the Arimidex, Tamoxifen Alone or
in Combination (ATAC) trial.
Table 2. HR for Univariable and Bivariable Models According to Subgroups
and Scores
Subgroup
No. of
Patients
No. of
Distant
Recurrences
Univariable Bivariable
HR 95% CI HR 95% CI
All 2,137 148
CTS 1.96 1.73 to 2.21 1.80 1.57 to 2.06
ROR 2.69 2.12 to 3.43 2.07 1.63 to 2.64
Node negative 1,580 76
CTS 1.96 1.50 to 2.57 1.56 1.15 to 2.12
ROR 2.56 1.83 to 3.56 2.11 1.48 to 3.00
Node positive 557 72
CTS 1.84 1.52 to 2.23 1.74 1.42 to 2.13
ROR 2.52 1.80 to 3.53 2.15 1.52 to 3.03
Node negative/
HER2
negative 1,455 70
CTS 2.12 1.61 to 2.79 1.65 1.21 to 2.24
ROR 3.00 2.11 to 4.27 2.41 1.65 to 3.50
NOTE. P values  .001 for all HRs except those in bold.
Abbreviations: CTS, Clinical Treatment Score; HER2, human epidermal
growth factor receptor 2; HR, hazard ratio; ROR, risk of recurrence.
Each variable added to the other variable.
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Fig 1. Kaplan-Meier curve for distant recurrence in years 5 to 10 in all patients
according to risk of recurrence risk groups. HR, hazard ratio.
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a node-positive tumor, and in those, CTS added most prognostic
information univariately (LR235.60) and when added to the ROR
score (LR 2 25.67). The ROR score added somewhat less but still
significant prognostic information for distant recurrence in this sub-
group (Table 2). 24.6% of women with node-positive disease were
categorized into the low-risk ROR group with a distant recurrence risk
of only 3.3% in the late follow-up period (Appendix Table A3). Over-
all, the effect size for the ROR score in the bivariable analyses was
similar across all subgroups (Table 2).
The correlation between the CTS and ROR was weak (r 0.36).
Agreement between the ROR score and CTS for separating patients
into low-, intermediate-, and high-risk groups is shown in Table 3.
The number of women categorized into the low-risk group was simi-
lar for the two scores (55.4% v 53.3%). However, the CTS categorized
overall more women into the intermediate-risk group (32.4%) than
the ROR score (25.2%), which categorized more women as high risk
(19.5% ROR v 14.3% CTS; Table 3). Furthermore, Appendix Fig A1
(online only) shows the reclassification of distant recurrence and
nonevents by ROR or CTS plus ROR versus CTS alone. For those with
distant recurrence, the ROR score classified 32 women into higher-
risk and 21 into lower-risk categories compared with the CTS alone.
This translates into a net reclassification of 7.4% for women with
distant recurrence. For nonevents, the reclassification by ROR was
small (1.5%). The overall NRI for ROR versus CTS was 5.97%,
which was not significant (P .3). The addition of ROR to the CTS
improved the classification for distant recurrence (14 women into
higher-risk v 3 women into lower-risk groups; net reclassification
of 7.4%) compared with CTS alone, but a net loss was observed for
women with nonevents (123 women into higher-risk v 161 into
lower-risk groups; net reclassification, 1.9%). For this comparison,
a significant NRI of 9.34% was observed (P .001; Appendix Fig
A1). Similar results were seen for women with node-negative dis-
ease (data not shown).
DISCUSSION
It is well known that recurrence risk extends for at least 20 years in
women with hormone receptor–positive early-stage breast cancer
treated with 5 years of endocrine therapy.23 Continued (extended)
adjuvant treatment beyond 5 years reduces recurrence rates but is
unlikely to be significantly beneficial to all patients individually. It is
therefore crucial to identify molecular markers that predict late recur-
rence. The analyses of combined data from the TransATAC and
ABCSG 8 trials showed that the ROR score added significant prognos-
tic information for late distant recurrence in women with hormone
receptor–positive early-stage breast cancer who did not receive che-
motherapy. Predefined risk stratification showed significant differ-
ences between ROR-defined risk groups with respect to 10-year late
distant recurrence.
The ROR score has previously been shown to add prognostic infor-
mation for recurrence in the two trials of endocrine-treated patients.11,18
The ROR score was able to predict the risk of distant recurrence in post-
menopausal women with early hormone receptor–positive early-stage
breast cancer.22 In the TransATAC trial, the ROR score added more
prognostic information than the Oncotype RS.18 In this combined anal-
ysis, the CTS was the stronger prognostic score for late distant recurrence
overall and for the node-positive subgroup. In contrast, the ROR score
was the stronger predictor of late distant recurrence for patients with
node-negative and node-negative/HER2-negative disease, who may be
spared further endocrine therapy, specifically those who were categorized
into the low-risk group by the ROR score.
The ROR score provided clinically useful prognostic informa-
tion, predicting risk of late distant recurrence beyond that of classical
clinical markers in all subgroups. Of note is that 24.6% of women with
node-positive disease were categorized into the ROR low-risk group
with a distant recurrence risk of only 3.3% in years 5 to 10. Given this
low risk of distant recurrence at both early and late follow-up periods,
the indication for adjuvant chemotherapy and the extension of endo-
crine therapy beyond 5 years are both questionable. Concerning the
node-negative population with HER2-negative disease, large tumor
size and premenopausal status at diagnosis have been suggested as fac-
tors to select women for extended adjuvant endocrine treatment.24-26
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Our results show that women with node-negative disease categorized
into the ROR low-risk group have an extremely low rate of late distant
recurrence despite some of them having large tumors, which chal-
lenges the indication for additional therapy. In contrast, women with
node-negative disease categorized into the high-risk group by the
ROR score might benefit from additional endocrine therapy, but this
needs further confirmation because the ROR score is a prognostic and
not predictive marker.
Strengths of this analysis included its large sample size (N 2,137),
long follow-up with a median of 10 years, and a patient population that
came from two well-characterized registration clinical trials using tamox-
ifen and anastrozole. One limitation was that none of these women re-
ceived chemotherapy as part of their initial treatment, and therefore we
areunabletoanalyzetheprognosticvalueoftheRORscorefor latedistant
recurrence in this group of patients. Baseline characteristics were some-
whatdifferentbetweenthetwotrials.WomenintheABCSG8trialhadan
overall low-to-intermediate risk of late distant recurrence, whereas those
in the TransATAC trial showed an increased risk, which is explained by
larger tumor size, the inclusion of grade 3 tumors (none in the ABCSG 8
trial), and the presence of more women with more than four positive
nodes. Analyses with exploratory exclusion of grade 3 tumors from the
TransATAC trial showed similar results. The combined analysis offered a
unique opportunity to investigate the prognostic value of the ROR score
in this clinically relevant population.
In summary, we showed that the ROR score provided addi-
tional clinically meaningful prognostic information for late distant
recurrence beyond standard clinical variables (CTS) and was able
to discriminate patients into low- and high-risk groups in this large
combined data set. The ROR score has been validated in several
trials,11,12,18 and the results presented here may help to identify
women who are at high risk of late distant recurrence and who may
benefit from extended endocrine treatment beyond 5 years. Con-
versely, the results show that the ROR score is able to identify
women who are at sufficiently low risk of late distant recurrence,
even in women with node-positive disease, so that they may be
spared prolonged and/or additional endocrine treatment and,
therefore, overtreatment.
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Table 3. Reclassification of Risk Groups by ROR v CTS and ROR Plus CTS v CTS Alone for All Patients
Risk Group
CTS
Low Intermediate High Total
No. % No. % No. % No. %
ROR
Low 855 287 41 1,183 55.4
Intermediate 216 252 70 538 25.2
High 68 154 194 416 19.5
Total 1,139 53.3 693 32.4 305 14.3 2,137
CTS plus ROR
Low 1,055 139 0 1,194 55.8
Intermediate 84 501 25 610 28.5
High 0 53 280 333 15.6
Total 1,139 53.3 693 32.4 305 14.3 2,137
NOTE. Cutoffs according to 10-year distant recurrence risk: low,  10%; intermediate, 10% to 20%; high,  20%.
Abbreviations: CTS, Clinical Treatment Score; ROR, risk of recurrence.
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GLOSSARY TERMS
anastrozole: a third-generation nonsteroidal aromatase inhib-
itor that prevents the conversion of androgen to estrogen in the
peripheral tissues in postmenopausal women. Because hormone-
dependent breast cancer progresses with estrogen, anastrozole
has been used in the treatment of breast cancer in postmeno-
pausal women. See aromatase inhibitors.
Cox proportional hazards regressionmodel: a statis-
tical model for regression analysis of censored survival data, ex-
amining the relationship of censored survival distribution to one
or more covariates. This model produces a baseline survival
curve, covariate coefficient estimates with their standard errors,
risk ratios, 95% CIs, and significance levels.
estrogen receptor (ER): ligand-activated nuclear proteins,
belonging to the class of nuclear receptors, present in many
breast cancer cells that are important in the progression of
hormone-dependent cancers. After binding, the receptor-ligand
complex activates gene transcription. There are two types of es-
trogen receptors (ER and ER). ER is one of the most impor-
tant proteins controlling breast cancer function. ER is present
in much lower levels in breast cancer, and its function is uncer-
tain. Estrogen receptor status guides therapeutic decisions in
breast cancer.
prognostic factor: a measurable patient characteristic that is associ-
ated with the subsequent course of disease (whether or not therapy is
administered). The identification of a prognostic factor does not neces-
sarily suggest a cause-and-effect relationship. However, within a suitable
outcome model, the measurement of a prognostic factor contributes to
an estimate of an outcome probability (eg, the probability of disease-free
survival within a given time interval).
recurrence score: a number between 0 and 100 that corresponds to
a specific likelihood of breast cancer recurrence within 10 years of initial
diagnosis. The score is derived from a mathematical function combining
the expression values of 16 breast cancer related genes and five reference
genes.
Sestak et al
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Appendix
Table A1. Description of Clinical and Multigene Scores
Score Abbreviation Details Reference
Clinical Treatment Score CTS Includes information on nodal status, grade, tumor size, age, and treatment. Score
developed on TransATAC data.
Cuzick et al17
Immunohistochemical
Score 4
IHC4 Includes information on ER, PgR, Ki-67, and HER2. Score developed on
TransATAC data. FFPE blocks used to extract RNA to perform IHC for ER, PgR,
Ki-67, HER2.
Dowsett et al,15 Cuzick et al,17
Zabaglo et al: J Clin Pathol
63:800-804, 2010
Oncotype Dx Recurrence
Score
RS Twenty-one-gene–based expression profile score using qRT-PCR (16 cancer
genes, five housekeeping genes). FFPE blocks used to extract RNA.
Paik et al: N Engl J Med 351:
2817-2826, 2004
Prosigna Risk of Recurrence
Score
ROR Fifty gene–based expression profile score using qRT-PCR. FFPE blocks used to
extract RNA to perform analysis on nCounter system.
Dowsett et al12
Breast Cancer Index BCI Multigene assay using qRT-PCR. Combination of two biomarkers: HOXB13/IL17BR
and molecular grade index.
Zhang et al,7 Sgroi et al8
EndoPredict EPClin Twelve gene–based expression profile score using qRT-PCR (eight cancer genes,
four housekeeping genes). FFPE blocks used to extract RNA to perform
analysis.
Dubsky et al9
Abbreviations: ER, estrogen receptor; FFPE, formalin-fixed paraffin-embedded; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry;
PgR, progesterone receptor; qRT-PCR, quantitative reverse transcriptase polymerase chain reaction; TransATAC, translational research cohort within the Arimidex,
Tamoxifen Alone or in Combination (ATAC) trial.
Table A2. Prognostic Baseline Factors According to ROR Risk Groups
Factor
ROR (%)
Low Intermediate High
Grade
Low 28.6 13.4 6.5
Intermediate 68.6 77.4 78.1
High 2.8 9.5 15.4
Negative nodal status 88.4 70.3 37.5
Tumor size  2 cm 16.7 35.1 53.6
Age  65 years 34.1 44.4 52.2
Abbreviation: ROR, risk of recurrence.
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Table A3. HR and 10-Year Distant Recurrence Risk According to Patient Subgroups and ROR Risk Groups
Variable No. of Patients HR 95% CI 10-Year Risk (%) 95% CI
All patients
Low 1,183 Reference 2.4 1.6 to 3.5
Intermediate 538 3.26 2.07 to 5.13 8.3 6.1 to 11.2
High 416 6.90 4.54 to 10.47 16.6 13.1 to 20.9
Node negative
Low 1,046 Reference 2.3 1.5 to 3.5
Intermediate 378 3.22 1.93 to 5.37 8.5 5.9 to 12.1
High 156 4.26 2.33 to 7.78 9.3 5.5 to 15.5
HER2 negative
Low 1,117 Reference 2.2 1.4 to 3.3
Intermediate 498 3.70 2.31 to 5.95 8.7 6.4 to 11.9
High 359 7.23 4.61 to 11.32 16.2 12.5 to 20.9
Node negative/HER2 negative
Low 983 Reference 2.0 1.3 to 3.2
Intermediate 344 3.75 2.19 to 6.41 9.0 6.2 to 13.0
High 128 5.49 2.92 to 10.35 11.5 6.8 to 19.0
Node positive
Low 137 Reference 3.3 1.2 to 8.6
Intermediate 160 3.16 1.04 to 9.61 7.8 4.4 to 13.8
High 260 7.94 2.87 to 21.92 20.9 16.1 to 26.9
Node positive with one to three nodes
Low 137 Reference 3.3 1.2 to 8.6
Intermediate 154 3.04 0.99 to 9.32 7.5 4.1 to 13.5
High 196 7.37 2.63 to 20.65 19.6 14.4 to 26.5
Node positive with four or more nodes
Low 0 — —
Intermediate 6 Reference 16.7 2.5 to 72.7
High 64 1.67 0.17 to 83.68 24.7 15.3 to 38.3
Abbreviations: HER2, human epidermal growth factor receptor 2; HR, hazard ratio; ROR, risk of recurrence.
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Fig A1. Net Reclassification Index (NRI) for distant recurrence (N 148) versus nonevents (N 1,989) for all patients. Left panel: gray-shaded area represent patients reclassified
into high-risk group by risk of recurrence (ROR); blue-shaded area represents patients reclassified into lower-risk group by ROR. Right panel: gray-shaded area represents patients
reclassified into high-risk group by Clinical Treatment Score (CTS) plus ROR; blue-shaded area represents patients reclassified into lower risk group by CTS plus ROR. NRI [distant
recurrence (%upward%downward)] – [nonevents (%upward%downward)]. NRI forROR/CTS [(32/148) (21/148)] – [(406/1,989) (377/1,989)]5.97%.NRI forROR/CTS
plus ROR  [(14/148)  (3/148)] – [(123/1,989)  (161/1,989)]  9.34%.
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